Jacob Bell
Senior Reporter | @realjacobbellJacob graduated from the University of Maryland with degrees in journalism and biology. He's previously reported on M&A at TheDeal, politics at McClatchy DC and education research at Education Week. His main interests include RuPaul's Drag Race, anything from the McDonalds menu and strong shoe game. He has loud opinions about avocado toast and Vine ending.
1464 articles by Jacob Bell
-
Wave shelves ALS drug following trial setback
May 23, 2023 -
Ironwood to buy rare disease drugmaker in billion-dollar deal
May 22, 2023 -
Moderna reports ‘encouraging’ early data for one of its rare disease medicines
May 19, 2023 -
Mustang pares research, sells manufacturing plant to save money
May 18, 2023 -
PTC’s drug for PKU succeeds in late-stage clinical trial
May 17, 2023 -
A struggling biotech wraps its main assets into a new drug company
May 12, 2023 -
Amylyx’s ALS drug again surpasses Wall Street expectations
May 11, 2023 -
Alzheimer’s doctors see promise, limits in Lilly’s latest drug data
May 10, 2023 -
Lilly’s new Alzheimer’s data may both help and hinder rival Biogen
May 3, 2023 -
FDA approves new ALS medicine in precedent-setting decision
April 25, 2023 -
Biogen’s new strategy brings more pipeline cuts, but leaves deal options open
April 25, 2023 -
Apellis’ immune system drug hits a setback in ALS
April 21, 2023 -
Merck’s latest deal turns up the spotlight on immune system drugmakers
April 17, 2023 -
A biotech startup with big-name backers aims to create new cancer medicines
April 14, 2023 -
Biogen, aiming for a better Alzheimer’s therapy, licenses a Denali program
April 13, 2023 -
Novo’s latest deal targets cell therapy for diabetes, obesity
April 12, 2023 -
A new biotech wants to ease a bottleneck in cell and gene therapy production
April 11, 2023 -
Ginkgo grows its gene therapy offerings with StrideBio deal
April 5, 2023 -
Biogen taps a deals expert in latest C-suite appointment
April 4, 2023 -
5 FDA decisions to watch in the second quarter
April 3, 2023 -
Cytokinetics to end late-stage study of ALS drug
March 31, 2023 -
A brain drug developer joins a growing list of biotech layoffs
March 30, 2023 -
Intra-Cellular shares rise on depression study’s success
March 28, 2023 -
ALS drugmakers, encouraged by recent FDA feedback, set their sights on a key protein
March 27, 2023 -
FDA advisers support conditional clearance of Biogen’s ALS drug
March 22, 2023